Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hyperbaric oxygen therapy (HBOT) vs control without HBOT Death at 1 year · any person with radiation tissue injury arising later than 6 months after irradiation (LRTI), including dysfunction or… Hyperbaric oxygen therapy for late radiation tissue injury (2023) · Cochrane | RR 0.93 [0.47, 1.83] | 3 studies · 166 participants | Low |
Hyperbaric oxygen therapy (HBOT) vs control without HBOT Complete or substantial improvement of condition · any person with radiation tissue injury arising later than 6 months after irradiation (LRTI), including dysfunction or… Hyperbaric oxygen therapy for late radiation tissue injury (2023) · Cochrane | RR 1.39 [1.02, 1.89] | 6 studies · 468 participants | Low |
Hyperbaric oxygen therapy (HBOT) vs control without HBOT Visual disturbances · any person with radiation tissue injury arising later than 6 months after irradiation (LRTI), including dysfunction or… Hyperbaric oxygen therapy for late radiation tissue injury (2023) · Cochrane | RR 4.03 [1.65, 9.84] | 5 studies · 438 participants | High |
Hyperbaric oxygen therapy (HBOT) vs control without HBOT Otic barotrauma · any person with radiation tissue injury arising later than 6 months after irradiation (LRTI), including dysfunction or… Hyperbaric oxygen therapy for late radiation tissue injury (2023) · Cochrane | RR 9.08 [2.21, 37.26] | 4 studies · 357 participants | High |
Hyperbaric oxygen therapy (HBOT) vs control without HBOT Wound dehiscence · any person with osteoradionecrosis of the jaw or at risk of osteoradionecrosis of the jaw Hyperbaric oxygen therapy for late radiation tissue injury (2023) · Cochrane | RR 0.24 [0.06, 0.94] | 2 studies · 264 participants | Low |
Hyperbaric oxygen therapy (HBOT) vs control without HBOT Pain score change at 12 months · any person with osteoradionecrosis of the jaw or at risk of osteoradionecrosis of the jaw Hyperbaric oxygen therapy for late radiation tissue injury (2023) · Cochrane | no estimate extracted | 2 studies · 157 participants | Moderate |
Hyperbaric oxygen therapy (HBOT) vs control without HBOT Complete resolution or significant improvement of osteoradionecrosis · any person with osteoradionecrosis of the jaw or at risk of osteoradionecrosis of the jaw Hyperbaric oxygen therapy for late radiation tissue injury (2023) · Cochrane | RR 1.26 [0.87, 1.82] | 3 studies · 239 participants | Low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Overall survival (OS) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.93 [0.83, 1.04] | 5 studies · 2006 participants | Moderate |
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 2: PLD alone vs other conventional chemotherapy Overall severe adverse events (grade > 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 2 studies · 964 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Anaemia (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 5 studies · 1968 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 6 studies · 2184 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 3 studies · 1222 participants | Very low |
Summary of findings 3: PLD with chemotherapy vs PLD alone Overall survival (OS) · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.92 [0.7, 1.21] | 1 study · 242 participants | Moderate |
Summary of findings 3: PLD with chemotherapy vs PLD alone Progression‐free survival (PFS) · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.94 [0.73, 1.22] | 2 studies · 353 participants | Low |
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 3: PLD with chemotherapy vs PLD alone Overall severe adverse events (grade ≥ 3) · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 2.48 [1.98, 3.09] | 1 study · 663 participants | Moderate |
Summary of findings 3: PLD with chemotherapy vs PLD alone Anaemia (grade ≥ 3) · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 2.38 [1.46, 3.87] | 2 studies · 785 participants | Moderate |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Progression‐free survival (PFS) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.81 [0.74, 0.89] | 5 studies · 2006 participants | Moderate |
Summary of findings 3: PLD with chemotherapy vs PLD alone Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 0.24 [0.14, 0.4] | 2 studies · 785 participants | Moderate |
Summary of findings 3: PLD with chemotherapy vs PLD alone Neurological (grade ≥ 3) · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 1.4 [0.85, 2.31] | 1 study · 663 participants | Low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Quality of life (QoL) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 1 study · 608 participants | Low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Overall severe adverse events (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 1.11 [0.95, 1.3] | 2 studies · 834 participants | Moderate |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Anaemia (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 1.37 [1.02, 1.85] | 5 studies · 1961 participants | Moderate |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 4.01 [1, 16.01] | 2 studies · 1028 participants | Very low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 0.38 [0.2, 0.74] | 4 studies · 1900 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Overall survival (OS) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.96 [0.77, 1.19] | 6 studies · 1995 participants | Moderate |
Summary of findings 2: PLD alone vs other conventional chemotherapy Progression‐free survival (PFS) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.94 [0.85, 1.04] | 4 studies · 1803 participants | Very low |
Chemotherapy with bevacizumab followed by maintenance bevacizumab vs chemotherapy alone Overall survival (OS) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | HR 0.97 [0.88, 1.07] | 2 studies · 2776 participants | Moderate |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Any adverse event grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | RR 1.31 [1.11, 1.55] | 1 study · 188 participants | Moderate |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | RR 6.49 [2.02, 20.87] | 1 study · 1352 participants | Low |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Overall survival (OS) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | HR 0.99 [0.79, 1.25] | 1 study · 1015 participants | Moderate |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Progression‐free survival (PSF) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | HR 0.93 [0.79, 1.09] | 1 study · 1015 participants | Moderate |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Any adverse event grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 1 study · 1011 participants | Moderate |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Overall survival (OS) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | HR 0.9 [0.79, 1.02] | 3 studies · 1564 participants | Moderate |
Chemotherapy with bevacizumab followed by maintenance bevacizumab vs chemotherapy alone Progression‐free survival (PFS) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | HR 0.82 [0.64, 1.05] | 2 studies · 2746 participants | Very low |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Progression‐free survival (PFS) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | HR 0.56 [0.5, 0.63] | 3 studies · 1564 participants | Moderate |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Quality of life (QoL) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 1 study · 486 participants | Low |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Any adverse event (grade ≥3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | RR 1.11 [1.07, 1.16] | 3 studies · 1538 participants | High |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Hypertension (grade ≥ 2) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Overall survival (OS) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | HR 0.86 [0.67, 1.11] | 1 study · 282 participants | Low |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Progression‐free survival (PFS) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | HR 0.56 [0.44, 0.72] | 1 study · 282 participants | Moderate |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 1 study · 146 participants | Low |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Any adverse events (grade ≥ 3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Hypertension (grade ≥ 2) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |